The HCPFive: Top News for Healthcare Providers from the Week of 08/16

Welcome to The HCPFive, your go-to roundup for the latest healthcare news and breakthroughs, curated specifically for busy healthcare professionals.Each week, we highlight 5 key developments or headlines from healthcare that you need to know — whether it's a cutting-edge treatment, regulatory updates, or innovations shaping the future of medicine.

This week's top stories include the US Food and Drug Administration (FDA) approval of an autoinjector formulation of lerodalcibep-liga (Lerochol) and an updated indication statement for MACE reduction, topline phase 3 data for avexitide in adults with post-bariatric hypoglycemia following Roux-en-Y gastric bypass surgery, the FDA’s acceptance of a New Drug Application (NDA) for ecopipam (EBS-101) in pediatric Tourette syndrome, the accelerated approval of pariglasgene brecaparvovec-opnr (Genglycos) for glycogen storage disease type Ia (GSD1a), and the FDA’s Fast Track designation of LTI-03 for idiopathic pulmonary fibrosis (IPF).

With The HCPFive, you'll get the essential takeaways to stay informed and ahead of the curve. Here's your quick dive into the top stories for the week of August 16, 2026 — let's jump in!

Lerodalcibep Autoinjector Receives FDA Approval for Hypercholesterolemia

On August 17, 2026, the FDA approved an autoinjector formulation of LIB Therapeutics’ lerodalcibep-liga (Lerochol), a third-generation PCSK9 inhibitor. The single-use device delivers the existing once-monthly, 300 mg/1.2 mL dose via a pressure-activated, single-motion injection completed in seconds.

The Agency also approved an updated indication statement for lerodalcibep-liga reflecting the established reduction in major adverse cardiovascular events (MACE) achieved through LDL-C lowering in adults with hypercholesterolemia treated with statins or with monoclonal antibody PCSK9 inhibitors added to statin therapy.

Avexitide Reduces Hypoglycemic Events in Phase 3 LUCIDITY Trial for PBH

On August 18, 2026, Amylyx Pharmaceuticals announced positive topline results from the phase 3 LUCIDITY trial evaluating avexitide in adults with post-bariatric hypoglycemia following Roux-en-Y gastric bypass (RYGB) surgery.The trial met its primary endpoint as agreed with the FDA, with the investigational glucagon-like peptide-1 (GLP-1) receptor antagonist reducing the composite rate of Level 2 and Level 3 hypoglycemic events by 55% compared with placebo (P = .000003). LUCIDITY also met all secondary endpoints.

FDA Accepts NDA for Ecopipam in Pediatric Tourette Syndrome

On August 19, 2026, the FDA accepted Teva Pharmaceuticals' NDA for ecopipam (EBS-101), a first-in-class selective D1 receptor antagonist, and granted Priority Review for the treatment of pediatric patients with Tourette syndrome, with a target action date late in the first quarter of 2027.

"If approved, ecopipam would be the first new therapy for Tourette syndrome in more than 10 years and the first novel mechanism of action in more than 50 years, offering patients and families a long-awaited new treatment option,” Eric Hughes, MD, PhD, executive vice president, Global R&D and chief medical officer, at Teva, said in a statement.

FDA Approves Gene Therapy for Glycogen Storage Disease Type 1a

On August 20, 2026, the FDA granted accelerated approval to pariglasgene brecaparvovec-opnr (Genglycos), a one-time AAV8 gene therapy, to reduce daily cornstarch intake as an adjunct to nutritional management in patients 8 years and older with GSD1a, making it the first approved treatment for the condition.

FDA Fast Tracks LTI-03 for Idiopathic Pulmonary Fibrosis

On August 20, 2026, the FDA granted Fast Track designation to LTI-03, an inhaled peptide therapy from Rein Therapeutics, for IPF. The decision follows a prior Orphan Drug designation already granted to LTI-03 for IPF, whose Caveolin-1-derived mechanism sets it apart from existing antifibrotics by targeting alveolar epithelial repair alongside fibrotic signaling.